Algert Global’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Algert Global’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-205,529	Closed	-$2.26M	–	400
2017 Q1	$2.26M	Buy	205,529 +32,072	+18%	+$372K	0.61%	53
2016 Q4	$2.35M	Buy	+173,457	New	+$2.42M	0.67%	18
2016 Q2	–	Sell	-19,232	Closed	-$210K	–	435
2016 Q1	$210K	Buy	19,232 +4,872	+34%	+$61.6K	0.08%	314
2015 Q4	$248K	Buy	+14,360	New	+$257K	0.12%	265
2014 Q3	–	Sell	-51,882	Closed	-$358K	–	339
2014 Q2	$358K	Buy	+51,882	New	+$367K	0.23%	166
2014 Q1	–	Sell	-99,846	Closed	-$939K	–	399
2013 Q4	$939K	Buy	99,846 +35,910	+56%	+$256K	0.25%	147
2013 Q3	$399K	Buy	63,936 +16,824	+36%	+$105K	0.11%	233
2013 Q2	$310K	Buy	+47,112	New	+$374K	0.1%	225

Other funds holding SCMP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Algert Global's SCMP Position: Q2 2017 in Review

Algert Global sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q2 2017, closing a stake of 205,529 shares — an estimated $2.26M sold.

Algert Global first reported a position in SCMP in Q2 2013 and held it in 8 quarters. The position peaked at $2.35M in Q4 2016. 167 funds tracked by Wall St. Rank hold SCMP as of Q2 2017.

Algert Global reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Algert Global sold 205,529 Sucampo Pharmaceuticals, Inc. shares in Q2 2017, an estimated $2.26M.
Algert Global first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 8 quarters.
Algert Global's Sucampo Pharmaceuticals, Inc. position peaked at $2.35M in Q4 2016.
167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q2 2017.

Based on Algert Global's 13F filing for Q2 2017, filed 1 Aug 2017.